Esther Rajavelu - 07 Nov 2024 Form 4 Insider Report for Spero Therapeutics, Inc. (SPRO)

Role
CFO & CBO
Signature
Maegan Deare, attorney-in-fact for Esther Rajavelu
Issuer symbol
SPRO
Transactions as of
07 Nov 2024
Net transactions value
-$53,008
Form type
4
Filing time
12 Nov 2024, 16:05:10 UTC
Previous filing
05 Feb 2024
Next filing
05 Feb 2025

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction SPRO Common Stock Sale $30,590 -23,351 -5.6% $1.31 396,515 07 Nov 2024 Direct F1
transaction SPRO Common Stock Sale $22,418 -17,245 -4.3% $1.30 379,270 08 Nov 2024 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The reported transaction is a sale of common stock effected to cover tax withholding obligations pursuant to a "sell to cover" provision included in each RSU Agreement in connection with the vesting of RSUs that were granted to the Reporting Person on November 13, 2023.